Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06947304 Sponsor: Corcept Therapeutics Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06947304
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your blood test shows a certain level of a liver enzyme called AST — above 17 U/L if you are a woman, or above 20 U/L if you are a man (this requirement may not apply if you had a qualifying liver biopsy within the last 12 months — confirm with trial site).
  • A special liver scan (MRI) shows that at least 8% of your liver is made up of fat, and this scan must be done within 4 weeks of your first study visit.
  • You have type 2 diabetes managed by diet alone or diet plus the medication metformin (at a stable dose for at least one month before screening), OR you have three or more features of metabolic syndrome, such as high blood sugar, high blood pressure, high triglycerides, low "good" cholesterol (HDL), or being overweight/obese with a larger waist size.
  • Other eligibility requirements may also apply — confirm with the trial site.

Who may not be able to join:

  • You have taken part in another clinical trial for liver disease (MASH) or weight loss in the last 3 months.
  • You have taken part in any other clinical trial within the last 3 months (or longer, depending on the treatment used).
  • You are pregnant, trying to become pregnant, or currently breastfeeding.
  • Your body mass index (BMI) is below 18 or above 45.
  • You regularly drink more than a moderate amount of alcohol (more than about 1.5 drinks/day for women or 2 drinks/day for men) within the past year.
  • A urine drug test comes back positive for amphetamines, cocaine, opiates, or cannabis.
  • You have been diagnosed with, or are suspected to have, severe liver scarring (cirrhosis) or signs that your liver is not working properly.
  • You have another chronic liver condition, such as hepatitis B or C, autoimmune hepatitis, or certain other liver diseases.
  • You have had a heart attack, severe chest pain (unstable angina), or stroke in the last 3 months.
  • Your blood pressure is not well controlled (above 160/100 mmHg).
  • You are currently taking certain medications that could interact with the study drug (confirm with trial site).
  • You are unable to have an MRI scan for any reason.
  • Other exclusion criteria may also apply — confirm with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kavita Juneja, MD, Corcept Therapeutics

Phone: (573) 882-5864

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Corcept Therapeutics
Registry
ClinicalTrials.gov
Start date
22 August 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in fasting hepatic lipogenesis after 6 weeks of treatment; Change in peak lipogenesis after 6 weeks of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov